2. Academic Validation
  3. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402

  • J Med Chem. 2010 Jan 28;53(2):798-810. doi: 10.1021/jm9014982.
Christoph M Dehnhardt 1,  Aranapakam M Venkatesan,  Efren Delos Santos,  Zecheng Chen,  Osvaldo Santos,  Semiramis Ayral-Kaloustian,  Natasja Brooijmans,  Robert Mallon,  Irwin Hollander,  Larry Feldberg,  Judy Lucas,  Inder Chaudhary,  Ker Yu,  Jay Gibbons,  Robert Abraham,  Tarek S Mansour
Affiliations

Affiliation

  • 1 Discovery Medicinal Chemistry, Wyeth Research, Pearl River, New York 10965, USA. dehnhac@wyeth.com
PMID: 19968288 DOI: 10.1021/jm9014982
Abstract

Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kalpha and mTOR, and excellent inhibition of cell proliferation in several human Cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce Apoptosis in Cancer cells. In addition, 3 showed excellent in vivo efficacy in various human Cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential Anticancer therapy.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z